Core Viewpoint - Hutchison China MediTech Limited (00013) has seen its stock price increase by 2.39% to HKD 23.98 following the announcement of positive results from the SACHI III clinical trial published in The Lancet [6]. Group 1: Company Announcement - On January 14, Hutchison China MediTech announced the results of the SACHI III trial, which studies the combination therapy of Savolitinib (沃瑞沙®) and Osimertinib (泰瑞沙®) for treating EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer patients who have disease progression after first-line EGFR TKI treatment [6]. - The SACHI study focuses on patients with MET amplification and evaluates the efficacy of the combination therapy [6]. Group 2: Drug Information - Savolitinib is a potent and highly selective oral MET TKI co-developed by AstraZeneca and Hutchison China MediTech, with AstraZeneca responsible for commercialization [6]. - Osimertinib is an irreversible third-generation EGFR TKI [6]. - Based on the data from the SACHI study, the combination therapy of Savolitinib and Osimertinib is expected to be approved in China by June 2025 [6].